Shattuck Labs is a US-based biotech company that develops cancer and autoimmune disease treatments. Its lead product candidate, SL-172154, is in Phase 1 clinical trial for ovarian, fallopian tube, and peritoneal cancers. The company also develops SL-279252 for advanced solid tumors and lymphoma. Founded in 2016, Shattuck Labs is headquartered in Austin, Texas.